Treatment-resistant schizophrenia: Clinical experience with new antipsychotics

European Neuropsychopharmacology

Volumn 6, Issue SUPPL.2, 1996, Pages

  Bondolfi, Guido ^a   Baumann, Pierre ^a   Dufour, Henri ^a  

^a DEPT UNIV DE PSYCHIATRIE ADULTE   (Switzerland)

Author keywords

Clozapine; Extrapyramidal side effects; Risperidone; Treatment resistant schizophrenia

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT; RISPERIDONE;

CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; PRIORITY JOURNAL; SCHIZOPHRENIA; ARTICLE;

CLOZAPINE; HUMANS; RISPERIDONE; SCHIZOPHRENIA;

EID: 0029949965     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0924-977x(96)00012-0     Document Type: Article

References (46)

1. Addington, D.E., Jones, B., Bloom, D., Chouinard, G., Remington, G. and Albright, P. (1993) Reduction of hospital days in chronic schizophrenic patients treated with rispendone: A retrospective study. Clin. Therapeut. 15, 917-926.
2. Amsler, H.A., Teerenhovi, L., Barth, E., Harjwla, K. and Vuopio, P. (1977) Agranulocytosis in patients treated with clozapine: a study of the Finnish epidemic. Acta Psychiatr. Scand. 56, 241-248.
3. Blin, O., Azorin, J.M. and Bouhours, P. (1996) Antipsychotic and anxiolytic properties of risperidone, haloperidol and methotrimeprazine in schizophrenic patients. J. Clin. Psychopharmacol. 16, 38-44.
4. Bondolti, G., Baumann, P. Patris, M., Maj, J.-P. and Billeter, U. (1995) A randomized, double-blind trial of risperidone versus clozapine for treatment-resistant chronic schizophrenia. Poster presented at the 8th ECNP Congress, Venice. 30 September-4 October 1995 Eur. Neuropsychopharmacol. 5, 349.
5. Breier, A., Buchanan, R.W., Kirkpatrick, B., Davis, O.R., Insh, D., Summerfelt, A. and Carpenter, W.T. (1994) Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am. J. Psychiatr. 151, 20-26.
6. Bryois, Chr. (1994) Nouvelles alternatives psychopharmacologiques au traitement de la schizophrenie. Arch. Suisses Neurol. Psychiatr. 145, 19-24.
7. Buchanan, R.W. and Carpenter, W.T. (1994) Domain of psychopathology: an approach to the reduction of heterogeneity in schizophrenia. J. Nerv. Ment. Dis. 182, 193-204
8. Chouinard, G., Jones, B., Remington, G., Bloom, D., Addington, D., McEwan, G. W., Labelle, A., Beauclair, L. and Arnott, W. (1993) A Canadian multi-centre placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J. Clin. Psychopharmacol. 13, 25-40.
9. Claghorn, J., Honigfeld, G., Abuzzahab, F. S., Wang, R., Steinbook, R., Tuason, V. and Kleman, G. (1987) The risks and benefits of clozapine versus chlorpromazine. J. Clin. Psychopharmacol. 7, 377-384.
10. Claus, A., Bollen, J., De Cuyper, H., Eneman, M. Malfroid, M., Peuskens, J. and Heylen, S. (1992) Risperidone verstis haloperidol in the treatment of chronic schizophrenic inpatients: a multi-centre double-blind comparative study. Acta Psychiatr. Scand. 85, 295-305.
11. Davis, S.A., Schaffer, C.B., Killian, G.A., Kinard, C. and Chan, C. (1980) Important issues in the drug treatment of schizophrenia. Schizophr. Bull. 6, 70-87.
12. Devinsky, O., Honigfeld, G. and Patin, J (1991) Clozapine-related seizures. Neurology 41, 369-371.
13. Fleischhacker, W.W., Meise, U., Gunther, V. and Kurz, M. (1994a) Compliance with antipsychotic drug treatment: intluence of side effects. Acta Psychtatr. Scand. 89 (Suppl. 382), 11-15.
14. Fleischhacker, W.W., Hummer, M., Kurz, M., Kurzthaler, I., Lieberman, J.A., Pollack, S., Safferman, A.Z. and Kane, J.M. (1994b) Clozapine dose in the Umted States and Europe: implications for therapeutic and adverse effects. J. Clin. Phychiatr. 55 (9, Suppl. B), 78-81.
15. Gerlach, J. (1991) New antipsychotics: classification, efticacy and adverse effects. Schizophr. Bull. 17, 289-310.
16. Gerlach, J., Thorsen, K. and Foy, K. (1975) Extrapyramidal reactions and amine metabolites in cerebrospinal tluid drives haloperidol and clozapine treatment of schizophrenic patients. Psychopharmacology 46, 341-350.
17. Gilbert, P.L., Harris, M.I., McAdams, L.A. and Jeste, D.V. (1995) Neuroleptic withdrawal in schizophrenic patients. Arch. Gen. Psychiatr. 52, 173-188.
18. Grant, S. and Fitton, A. (1994) Risperidone: a review of its pharmacology and therapeutic potential in the treatment of schizophicnia. Drugs 48, 253-273.
19. Guy, W. (Ed.) (1976) ECCDHU Assessment manual for psychopharmacology (revised). National Institutes of Mental Health, Rockville, MD, DHEW publication no. (ADM) 76-338.
20. Hoyberg, O.J., Fensho, C., Remvig, J., Lingjaerde, O., Sloth-Nielsen, M. and Salvesen, I. (1993) Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations. Acta Psychiatr. Scand. 88, 395-402.
21. Huttunen, M.O. Piepponen, T., Ratanen, H., Larmo, I., Nyholm, R., and Raitasoo, V. (1995) Risperidone versus zuelopenthial in the treatment of acute schizophrenic episodes: a double-blind parallel group trial. Acta Psychiatr. Scand. 91, 271-277.
22. Kane, J.M., Honigfeld, G., Singer, J., Meltzer, H. and the Clozaril collaborative study group. (1988) Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch. Gen. Psychiatr. 45, 789-796.
23. Kane, J.M. (1994) Risperidone. Am. J. Psychiatr. 151, 802-803.
24. Kane, J.M. (1989) The current status of neuroleptic therapy. J. Clin. Psychiatr. 50, 322-328.
25. Kay, S.R., Fiszbein, A. and Opler, L.A. (1987) The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr. Bull. 13, 261-276.
26. Klieser, E., Lehmann, E., Kinzler, E., Wurthmann, C. and Heinrich, K. (1995) Randomized, double-blind, controlled trial of resperidone versus clozapine in patients with chronic schizophrenia. J. Clin. Psychopharmacol. 15 (Suppl. 1). 45S-51S.
27. Krupp, B. and Barnes, P. (1992) Clozapine associated agranulocylosis: risk and aetiology. Br J. Psychiatr. 160 (Suppl. 17), 38-40.
28. Lader, M. (1992) Clozapine: a summary, Br. J. Psychiatr. 160 (Suppl. 17), 65-66.
29. Leadbetter, R., Shutty, M., Pavalonis, D., Vieweg, V., Higgins., P. and Downs, M (1992) Clozapine-induced weight gain: prevalence and clinical relevance. Am. J. Psychiatr. 149, 68-72.
30. Lewander, T. Westerber, S.E. and Morrison, D. (1990) Clinical profile of remoxipride: a combined analysis of a comparative double-blind multi-centre trial programme. Acta Psychiatr. Scand. Suppl. 358, 92-98.
31. Lieberman, J.A. and Alvir, J.M. (1992) A report of clozapine induced agranulocytosis in the United States Drug Safety 7 (Suppl. 1), 1-2.
32. Lieberman, J.A., Safferman, A.Z., Pollack, S., Szymanski, S., Celeste, J., Howard, A., Kronig, M., Bookstein, P. and Kane, J.M. (1994) Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. Am. J. Phychiatr. 151, 1744-1752.
33. Lieberman, J.A., Saltz, B.L.,. Johns, C.A., Pollack, S., Borestein, M. and Kane, J. (1991) The effects of clozapine on tardive dyskinesia. Br. J. Psychiatr. 158, 503-510.
34. Lindström, E. (1995) Efficacy and safety of risperidone in the long-term treatment of patients with schizophrema. Clin. Ther. 17, 402-412.
35. Marder, S.R. and Meibach, R.C. (1994) Risperidone in the treatment of sehizophrenia. Am. J. Psychiatr. 151, 825-835.
36. Marder, S.R., Wirshing, W.C. and Van Putten, T. (1991) Drug treatment of schizophrenia: overview of recent research. Schizophr. Res. 4, 81-90.
37. Meltzer, H.Y. and Okayli, G. (1995) Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am. J. Psychiatr. 152, 1883-1890.
38. Meltzer, H.Y., Cola, P. Way, L., Thompson, P.A., Bastani, B., Davies, M.A. and Snitz, B. (1993) Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia. Am. J. Psychiatr. 150, 1630-1638.
39. Möller, H.-J. (1995) The negative component in schizophrenia. Acta Psychiatr. Scand. 91 (suppl. 388). 11-14.
40. Peuskens, J., on behalf of the Risperidone Study Group. (1995) Risperidone in the treatment of patients with chronic schizophrenia: a multi-national multi-centre, double-blind, parallel-group study versus halopendol. Br. J. Psychiatr. 166, 712-726.
41. Pickar, D. Owen, R.R., Litman, R.E., Konicki, E., Gutierrez, R. and Rapoport, M.H. (1992) Clinical and biologic response to clozapine in patients with schizophrenia: crossover comparison with fluphenazine. Arch. Gen. Psychiatr. 49, 345-353.
42. Poulsen, V.J., Noring, V., Fog, R. and Gerlach, J. (1985) Tolerability and therapeutic effect of clozapine. Acta Psychiatr. Scand. 71, 176-185.
43. Scandinavian Society of Psychopharmacology Committee of Clinical Investigations (UKU). (1987) The UKU side effect rating scale: scale for the registration of unwanted effects of psychotropics. Acta Psychiatr. Scand. Suppl. 334, 81-44.
44. Strauss, J.J. and Carpenter, W.T. (1972) The prediction of outcome in schizophrenia. I: Characteristics of outcome. Arch. Gen. Psychiatr. 27, 739-746.
45. Van Putten, T. (1974) Why do schizophrenic patients refuse to take their drugs. Arch. Gen. Psychiatr. 31, 67-72.
46. Wadworth, A.N. and Heel, R.C. (1990) Remoxipride: a review of its pharmacodynamic and pharmacokinetic properties. Drugs 40, 863-879.